Cardinal Health, Inc. (CAH) FinancialsCAHFinancialCardinal Health, Inc.

Cardinal Health, Inc. (CAH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cardinal Health At Home, accounting for 1.7% of total sales, equivalent to $1.11B. Other significant revenue streams include Nuclear Precision Health Services and Opti freight logistics. Understanding this composition is critical for investors evaluating how CAH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cardinal Health, Inc. maintains a gross margin of 3.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.32%, while the net margin is 0.63%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CAH converts its operational activities into shareholder value.

In the context of the broader market, CAH competes directly with industry leaders such as COR and HSIC. With a market capitalization of $54.69B, it holds a significant position in the sector. When comparing efficiency, CAH's gross margin of 3.87% stands against COR's 3.95% and HSIC's 29.81%. Such benchmarking helps identify whether Cardinal Health, Inc. is trading at a premium or discount relative to its financial performance.

Cardinal Health reported a total revenue of $636.72 billion in Q4 2026, with a gross profit margin of 3.87%, reflecting solid operational efficiency. The company also has a forward P/E ratio of 18.94, suggesting it is reasonably valued for its growth potential.